📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-14 16:20
631 analysed today
631
Today
134,273
All-time analysed
40,194
Positive
6,287
Negative
79,947
Neutral
7,777
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
7 announcements match the current filters (relevance ≥ 5).
44% PAT Growth in Q1 FY27; EBITDA Margins Expand to 18% on Export Recovery
Sanjivani Paranteral reported a strong start to FY27 with total income rising 33.8% YoY to ₹23.99 Cr. Net profit grew 43.9% to ₹2.49 Cr, driven by a 61% surge in EBITDA as margins expanded by 305 bps to 18.01%. The performance was heavily anchored by exports, which contributed 90.5% of revenue (₹17.61 Cr), particularly from core markets in Latin America, CIS, and the Middle East. The company also noted a gradual scale-up of its Pune IV Fluid facility, which is expected to drive future volumes.
Confidence: HIGH
What changedThe company has demonstrated a significant margin expansion from its TTM average of 14.5% to 18.01% in Q1 FY27, alongside a recovery in its core export markets.
Why it mattersFor a micro-cap company with a ₹227 Cr market cap, achieving nearly 37% of its previous year's total revenue in a single quarter indicates strong growth momentum and potential for a full-year earnings re-rating.
Q1 FY27 Total Income: ₹23.99 CrYoY PAT Growth: 43.94%EBITDA Margin: 18.01%Export Revenue Share: 90.50%Q1 Revenue vs TTM Revenue: 36.91%
📅 Short termThe stock is likely to react positively to the margin expansion and strong bottom-line growth, reflecting improved operational efficiency.
📈 Long termStructural growth depends on the successful scale-up of the Pune facility and the company's ability to maintain high margins while expanding its product portfolio in domestic markets.
⚠ Risk flags
- High geographic concentration (90.5% exports)
- Relatively low promoter holding (31.3%)
- Small scale of operations making it sensitive to individual contract timings
Key Highlights
Total Income grew 33.81% YoY to ₹23.99 Cr for the quarter ended June 2026.
EBITDA margins improved significantly by 305 basis points to 18.01%.
Exports contributed 90.50% of total revenue, amounting to ₹17.61 Cr, showing 33.49% YoY growth.
Injectables segment remains the primary revenue driver, contributing 56.59% (₹11.01 Cr) of operations.
Net Profit (PAT) increased 43.94% YoY to ₹2.49 Cr compared to ₹1.73 Cr in the previous year.
👀 What to Watch
Monitor the utilization levels and commercialization progress of the Pune IV Fluid facility, as it is a key driver for future scale. Investors should also watch for any diversification in the domestic market to mitigate the 90%+ export concentration risk.
Sanjivani Paranteral Targets ₹145 Cr Revenue in FY27, Driven by New IV Fluid Plant Ramp-up
Sanjivani Paranteral has transitioned to a multi-vertical platform with the commissioning of its Pune IV fluid facility, which has a 60 million bottle annual capacity. Management has issued an aggressive revenue guidance of ₹145 cr for FY27, a ~123% increase over FY26 revenue of ₹64.8 cr. The new IV fluid vertical alone is expected to contribute ₹60-65 cr in FY27, effectively doubling the company's historical revenue base. While the company maintains a low debt-to-equity ratio of 0.19x, the focus now shifts to executing the guided utilization ramp-up from 40% to 70% through the fiscal year.
Confidence: HIGH
What changedThe company has completed its major capex phase and is now entering a high-growth revenue phase led by the new IV fluid vertical and European JV expansion.
Why it mattersThe expansion effectively doubles the company's scale, moving it from a ₹65 cr revenue base to a guided ₹145 cr base, which could lead to significant operating leverage if EBITDA margins hold at the guided 17-18% for the new vertical.
FY27 Revenue Guidance: ₹145 crGuidance vs TTM Revenue: 223%IV Fluid Capacity: 60 Mn bottles/yrDebt to Equity: 0.19xQ1 FY27 Injectable Revenue: ₹11.01 cr
📅 Short termThe market is likely to react positively to the clear growth roadmap and the substantial revenue jump guided for the current fiscal year.
📈 Long termIf the company successfully scales its IV fluid and nutraceutical verticals, it structurally transforms from a small-cap injectable player into a diversified international pharma platform.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Execution risk in achieving 70% capacity utilization
- High export concentration (78.5%)
- Regulatory risks associated with international plant certifications
Key Highlights
FY27 revenue guidance set at ₹145 cr, compared to ₹64.8 cr achieved in FY26.
New Pune IV fluid plant adds 60 million bottles per year capacity, with utilization guided to reach 70% by Q4 FY27.
IV fluid segment generated ₹4.38 cr in Q1 FY27, with a full-year target of ₹60-65 cr.
Exports remain the core driver, accounting for 78.5% of FY26 revenue across 25 countries.
Promoter stake has increased from 28.87% in June 2025 to 31.26% as of March 2026.
👀 What to Watch
Investors should monitor the quarterly utilization levels of the Pune IV fluid plant and the progress of the Prague JV majority stake negotiations, which could provide further inorganic growth.
Sept 16 AGM Set as Sanjivani Paranteral Approves Q1 FY27 Results and FY26 Annual Report
Sanjivani Paranteral's board approved the unaudited financial results for Q1 FY27 (ended June 30, 2026) on August 14, 2026. This follows a fiscal year (FY26) where revenue declined 7.6% to ₹64.76 Cr compared to ₹70.1 Cr in FY25. The company has scheduled its 32nd Annual General Meeting (AGM) for September 16, 2026, via video conferencing. A book closure period for share transfers is set from September 10 to September 16, 2026.
Confidence: HIGH
What changedThe company has finalized its Q1 FY27 financial performance review and established the timeline for its annual shareholder meeting and book closure.
Why it mattersThis is a standard regulatory requirement that provides shareholders with the first performance update of the new fiscal year and a platform for engagement at the AGM.
AGM Date: September 16, 2026Book Closure Start: September 10, 2026FY26 Revenue: ₹64.76 CrTTM Revenue: ₹65 CrMarket Cap: ₹227 Cr
📅 Short termThe stock may react to the specific Q1 earnings figures once the detailed tables are analyzed by the market.
📈 Long termLimited structural impact as this is a routine administrative and earnings approval meeting.
Key Highlights
Approved unaudited financial results for the first quarter ended June 30, 2026
32nd Annual General Meeting scheduled for September 16, 2026
Book closure period for members set from September 10, 2026, to September 16, 2026
Board meeting conducted and concluded within 60 minutes (1:00 PM to 2:00 PM)
Appointment of HD & Associates as Scrutinizer for the upcoming AGM e-voting
👀 What to Watch
Investors should examine the full Q1 FY27 results to determine if the company has recovered from the sequential revenue drop seen in March 2026 (₹10.51 Cr vs ₹20.86 Cr in Dec 2025).
Sanjivani Paranteral Approves Q1 Results; 32nd AGM Scheduled for Sept 16, 2026
Sanjivani Paranteral's board has approved the unaudited financial results for the quarter ended June 30, 2026. The company has scheduled its 32nd Annual General Meeting (AGM) for September 16, 2026, to be conducted via video conferencing. Additionally, the register of members and share transfer books will be closed from September 10 to September 16, 2026. The board also finalized the Annual Report and Director’s Report for the financial year 2025-26.
Confidence: HIGH
What changedThe company has formally approved its first-quarter financials for the new fiscal year and set the timeline for its annual shareholder meeting.
Why it mattersThis is a routine but essential regulatory requirement that provides shareholders with the latest financial performance data and a platform for engagement at the upcoming AGM.
AGM Date: 16th September, 2026Book Closure Start: 10th September, 2026TTM Revenue: Rs 64.76 CrMarket Cap: Rs 227 Cr
📅 Short termThe stock may see neutral to range-bound movement as the market processes the Q1 results relative to the previous year's June quarter revenue of Rs 17.89 Cr.
📈 Long termLimited structural impact as this is a routine financial reporting and governance event.
⚠ Risk flags
- Relatively low promoter holding at 31.3%
Key Highlights
32nd Annual General Meeting (AGM) scheduled for September 16, 2026
Book closure period of 7 days from September 10 to September 16, 2026
Board meeting duration of 60 minutes (1:00 PM to 2:00 PM)
Approval of the Annual Report and Director’s Report for FY 2025-26
👀 What to Watch
Investors should review the detailed Q1 FY27 financial statements to check for revenue recovery following the sequential decline to Rs 10.51 Cr in the March 2026 quarter.
Rs 7.37 Cr Preferential Issue of Warrants to Promoter at Rs 147.39
Sanjivani Paranteral's board has approved the issuance of 5,00,000 fully convertible warrants to promoter Mr. Ashwani Khemka at a price of Rs 147.39 per warrant. The total fundraise aggregates to Rs 7.37 crore, which represents approximately 15.3% of the company's current net worth of Rs 48 crore. The warrants are convertible into equity shares within 18 months, and the issue price is slightly above the current market price of Rs 146.8. This infusion will increase the specific promoter's individual stake from 29.88% to 32.62% upon full conversion.
Confidence: HIGH
What changedThe company is initiating a preferential fundraise from its promoter, which will lead to a capital infusion of Rs 7.37 Cr and a subsequent increase in promoter equity holding.
Why it mattersThe fundraise provides a liquidity boost equivalent to 15% of the company's net worth, signaling promoter confidence despite the stock's 39% decline over the past year. The capital can support the company's pharmaceutical operations which currently generate a 19.3% ROCE.
Total Issue Value: Rs 7.37 CrIssue Price per Warrant: Rs 147.39Fundraise vs Net Worth: ~15.3%Fundraise vs Market Cap: ~4.1%Post-Issue Promoter Stake (Individual): 32.62%
📅 Short termThe news is likely to be viewed positively as the promoter is subscribing at a price (Rs 147.39) slightly higher than the current market price (Rs 146.8), providing a floor for the stock.
📈 Long termThe infusion of capital into this small-cap pharma company strengthens its balance sheet for potential expansion, though the impact depends on the effective deployment of funds into the subsidiary.
⚠ Risk flags
- Equity dilution for minority shareholders
- Material related party transactions with subsidiary SPL Infusion Private Limited
Key Highlights
Issuance of 5,00,000 fully convertible warrants to promoter Mr. Ashwani Khemka
Total capital infusion of Rs 7,36,95,000 (Rs 7.37 Cr) at an issue price of Rs 147.39
Promoter's individual shareholding to increase from 29.88% to 32.62% post-conversion
Warrants are convertible into equity shares within a maximum period of 18 months
Board also approved material related party transactions with subsidiary SPL Infusion Private Limited
👀 What to Watch
Investors should monitor the upcoming postal ballot for shareholder approval and track the utilization of these funds, particularly regarding the material related party transactions with the subsidiary.
Rs 7.37 Cr Preferential Warrant Issue to Promoter at Rs 147.39
Sanjivani Paranteral's board has approved a preferential issue of 5,00,000 fully convertible warrants to promoter Mr. Ashwani Khemka, aggregating to Rs 7.37 crore. The warrants are priced at Rs 147.39 each, which is a marginal premium to the current market price of Rs 146.8. This capital infusion represents approximately 15.4% of the company's current net worth (Rs 48 Cr) and will increase the individual promoter's stake from 29.88% to 32.62% upon conversion. The board also approved material related party transactions with its subsidiary, SPL Infusion Private Limited, pending shareholder approval.
Confidence: HIGH
What changedThe company is initiating a capital infusion from its promoter and seeking approval for material transactions with its subsidiary.
Why it mattersPromoter capital infusion at current market prices signals internal confidence, especially after a 39.4% share price decline over the last 12 months. The funds will strengthen the balance sheet of this micro-cap pharma player.
Fundraise amount: Rs 7.37 CrIssue Price: Rs 147.39Fundraise vs Net Worth: ~15.4%Post-issue individual promoter stake: 32.62%Conversion period: 18 months
📅 Short termThe announcement is likely to be viewed positively by the market as the promoter is infusing capital at a price slightly above the current market rate.
📈 Long termThe infusion strengthens the equity base and provides growth capital, though the long-term impact depends on the execution of the related party transactions and subsidiary performance.
⚠ Risk flags
- Equity dilution for minority shareholders
- Related party transaction risks with subsidiary
Key Highlights
Issue of 5,00,000 fully convertible warrants to promoter Mr. Ashwani Khemka at Rs 147.39 per warrant.
Total fundraise amount of Rs 7,36,95,000 (Rs 7.37 Cr) to be received in cash.
Individual promoter shareholding to increase from 29.88% to 32.62% post-conversion.
Warrants are convertible into equity shares within a maximum period of 18 months from allotment.
Approval of material related party transactions with subsidiary SPL Infusion Private Limited.
👀 What to Watch
Investors should monitor the upcoming postal ballot for shareholder approval and watch for disclosures regarding the specific end-use of the Rs 7.37 crore proceeds.
Board meeting on July 23 to consider fundraise via warrants or convertible securities
Sanjivani Paranteral has scheduled a board meeting for July 23, 2026, to evaluate raising capital through warrants, convertible securities, or a preferential/rights issue. The company currently has a market capitalization of Rs 178 Cr and a low debt-to-equity ratio of 0.19. This move follows a period of declining stock performance, with a 12-month return of -41.1%. Investors should monitor the board's decision for the specific quantum of funds and the potential impact on the current promoter holding of 31.26%.
Confidence: HIGH
What changedThe company is initiating a formal process to raise fresh capital, which was not previously part of its immediate financial structure.
Why it mattersFor a small-cap pharma company with Rs 65 Cr revenue, a significant fundraise could provide capital for expansion or R&D, but it also introduces the risk of equity dilution for existing shareholders.
Board Meeting Date: July 23, 2026Market Cap: Rs 178 CrTTM Revenue: Rs 65 CrPromoter Holding: 31.26%Debt-to-Equity: 0.19
📅 Short termExpect price volatility as the market anticipates the terms of the fundraise and the potential entry of new investors.
📈 Long termThe impact depends on the utilization of proceeds; successful deployment into capacity or new markets could scale the business beyond its current Rs 70 Cr annual revenue range.
⚠ Risk flags
- Equity dilution risk
- Low promoter holding (31.26%)
- Uncertainty regarding issue price and use of proceeds
Key Highlights
Board meeting scheduled for July 23, 2026, to discuss multiple fundraising modes.
Proposed instruments include warrants, convertible securities, preferential issues, or rights issues.
Company market capitalization is Rs 178 Cr against a TTM revenue of Rs 65 Cr.
Promoter holding stands at 31.26% as of March 2026, which may be impacted by the fundraise.
Trading window remains closed until 48 hours after the June 2026 quarter results.
👀 What to Watch
Monitor the outcome of the July 23 board meeting for details on the fundraise size, pricing, and the identity of potential allottees if a preferential issue is chosen.
